These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29968861)

  • 1. [Checkpoint inhibitors in the decision-making algorithm of advanced non-small-cell lung cancer.].
    Fasola G; De Carlo E; Grossi F
    Recenti Prog Med; 2018 Jun; 109(6):328-332. PubMed ID: 29968861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Schvartsman G; Peng SA; Bis G; Lee JJ; Benveniste MFK; Zhang J; Roarty EB; Lacerda L; Swisher S; Heymach JV; Fossella FV; William WN
    Lung Cancer; 2017 Oct; 112():90-95. PubMed ID: 29191606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer.
    Martinez P; Peters S; Stammers T; Soria JC
    Clin Cancer Res; 2019 May; 25(9):2691-2698. PubMed ID: 30642913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitors in non-small-cell lung cancer: current status and future directions.
    Yan YF; Zheng YF; Ming PP; Deng XX; Ge W; Wu YG
    Brief Funct Genomics; 2019 Mar; 18(2):147-156. PubMed ID: 30247518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges.
    Meng X; Liu Y; Zhang J; Teng F; Xing L; Yu J
    Cancer Lett; 2017 Oct; 405():29-37. PubMed ID: 28688973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review.
    Ellis PM; Vella ET; Ung YC
    Clin Lung Cancer; 2017 Sep; 18(5):444-459.e1. PubMed ID: 28416123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?
    Tanvetyanon T; Gray JE; Antonia SJ
    Expert Opin Biol Ther; 2017 Mar; 17(3):305-312. PubMed ID: 28064556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
    Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
    Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapy in non-small cell lung cancer patients: back to the future.].
    Roberto M; Botticelli A; Cecere F; Cognetti F; Giusti R; Gelibter A; Lugini A; Nelli F; Nuti M; Santini D; Marchetti P
    Recenti Prog Med; 2019 Dec; 110(12):587-593. PubMed ID: 31909761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress of immune checkpoint inhibitors in neoadjuvant therapy of non-small cell lung cancer].
    Chen XY; Yang F
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):872-877. PubMed ID: 31694138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
    Li H; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):131-140. PubMed ID: 33508897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy.
    Valecha GK; Vennepureddy A; Ibrahim U; Safa F; Samra B; Atallah JP
    Expert Rev Anticancer Ther; 2017 Jan; 17(1):47-59. PubMed ID: 27841044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].
    Lantuejoul S; Adam J; Girard N; Duruisseaux M; Mansuet-Lupo A; Cazes A; Rouquette I; Gibault L; Garcia S; Antoine M; Vignaud JM; Galateau-Sallé F; Sagan C; Badoual C; Penault-Llorca F; Damotte D;
    Ann Pathol; 2018 Apr; 38(2):110-125. PubMed ID: 29571563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
    BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
    Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
    J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.
    Calles A; Riess JW; Brahmer JR
    Am Soc Clin Oncol Educ Book; 2020 May; 40():372-384. PubMed ID: 32421452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.